GSK opens API facility in Scotland

By Flora Southey

- Last updated on GMT


Related tags Vaccine Immune system Aids

GlaxoSmithKline has officially opened its aluminium salts facility in Montrose, Scotland.

According to GSK, the facility represents a £44m investment which, when fully operational in 2019, will provide ingredients for more than 40 million vaccinations a year.

The company told in-PharmaTechnologist the plant will create 15 jobs, on a site which employs more than 450.

The salts plant is situated within GSK’s Montrose facility, which has been making drug ingredients – including APIs for respiratory and HIV vaccine products – for six decades.

UK shake-up

Last month, GSK announced​ it would restructure its UK network by suspending plans for its Ulverston, Italy-based biopharma plant.

In addition, the firm suggested it would sell its cephalosporin antibiotics business and associated facilities, and invest in HIV and respiratory drug capacity.

The company said it is simplifying its business by improving competitiveness of its manufacturing network and increasing focus on its core business.

Related news

Related products

A Guide Through the API Drug Development Pipeline

A Guide Through the API Drug Development Pipeline

Content provided by Lonza Small Molecules | 11-Jul-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

Related suppliers

Follow us


View more